Hengrui Medicine: The application for market approval of Hequ Bopa Ethanolamine tablets has been accepted.

Hengrui Medicine announced on the evening of August 12th that the company's application for the market approval of Hepatopaclitaxel Ethanolamine Tablets has been accepted by the National Medical Products Administration. The drug is suitable for adult patients and children aged 6 and above with persistent and chronic primary immune thrombocytopenia who have had inadequate responses to previous treatments with glucocorticoids, immunoglobulins, etc.